Aim: The aim was to identify the prescription trends and risk factors that heart failure patients deal
with.
Background: Heart failure is a complicated clinical syndrome characterized by the heart's ability
to pump or fill with blood may decrease. It is a highly growing worldwide public health problem.
It continues to be a significant cause of illness and death worldwide. Auditing the prescription of
heart failure patients and analyzing the risk factor of it can reduce morbidity, mortality, and health
expenditure. The research made it easier to analyze the heart failure patients' prescription patterns
and risk factors who were hospitalized at Mallige Hospital in Bangalore. The study objectives were
to analyze prescribing patterns, identify risk factors, and evaluate prescription rationale.
Result: In most of the cases it shows that 54.5% were male patients, the age group of most of the
patients was 61-70 years. When risk factors were analyzed, it was discovered that hypertension
(77.7% of risk factors) and low sodium diet (43.1%) were the two most frequently prescribed risk
factors. The most commonly prescribed drug was diuretics (63.4%) Furosemide (62.6%) was the
most common drug. Followed by statin and fibrinolytic namely, atorvastatin, rosuvastatin, aspirin,
and clopidogrel. Conclusion: According to the study, dual and multiple drug combinations were usually provided
after prescription diuretics as a common medication. The most prevalent risk factor was discovered
to be hypertension, and this includes aspirin, clopidogrel, atorvastatin, and rosuvastatin for patients
with heart failure. In addition, we have found that most of the patients were taking statins and few
of them are having myalgia, as we all know statins are well known for their adverse drug reaction
which is rhabdomyolysis so as a pharmacist intervention, we suggested the physicians change the
drug to other lipid-lowering drugs like bempedoic acid and gave patients counseling regarding the
condition.
Keywords: Heart failure, prescription pattern, risk factor analysis, congestive cardiac
failure, cardiovascular drugs, Monotherapy, diuretics, and dual therapy.
Publication date: 01/10/2024
https://ijbpas.com/pdf/2024/October/MS_IJBPAS_2024_8383.pdf
Download PDF
https://doi.org/10.31032/IJBPAS/2024/13.10.8383
